Published in Oral Oncol on March 21, 2011
mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer. ISRN Otolaryngol (2012) 0.85
Autophagic action of new targeting agents in head and neck oncology. Cancer Biol Ther (2012) 0.85
Biologic therapy in head and neck cancer: a road with hurdles. ISRN Oncol (2012) 0.78
Treatment of recurrent metastatic head and neck cancer: focus on cetuximab. Clin Med Insights Ear Nose Throat (2012) 0.78
Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines. Invest New Drugs (2015) 0.76
Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med (2013) 2.96
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol (2014) 2.17
K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res (2008) 1.86
Atypical patterns of circadian clock gene expression in human peripheral blood mononuclear cells. J Mol Med (Berl) (2005) 1.73
Candidate mechanisms for capecitabine-related hand-foot syndrome. Br J Clin Pharmacol (2008) 1.27
ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis. Clin Cancer Res (2011) 1.26
Expression of a mutant HSP110 sensitizes colorectal cancer cells to chemotherapy and improves disease prognosis. Nat Med (2011) 1.23
Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. Pharmacogenetics (2004) 1.21
Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin Cancer Res (2006) 1.20
Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol (2002) 1.19
Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br J Clin Pharmacol (2010) 1.11
ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine. Clin Cancer Res (2003) 1.06
Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum Genet (2010) 1.01
Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer. Oral Oncol (2005) 1.00
Modeling of salivary production recovery after radiotherapy using mixed models: determination of optimal dose constraint for IMRT planning and construction of convenient tools to predict salivary function. Int J Radiat Oncol Biol Phys (2008) 1.00
Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer. Pharmacogenomics (2007) 1.00
Free-flap head and neck reconstruction and quality of life: a 2-year prospective study. Laryngoscope (2008) 0.99
Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients. Br J Clin Pharmacol (2011) 0.97
Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity. Br J Clin Pharmacol (2007) 0.97
Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5'-deoxy-5-fluorouridine on human keratinocytes. Anticancer Drugs (2004) 0.96
Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet Genomics (2007) 0.96
Optimized blood sampling with cytidine deaminase inhibitor for improved analysis of capecitabine metabolites. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 0.94
KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature. J Clin Oncol (2008) 0.93
Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC Cancer (2011) 0.92
Influence of the VEGF-A 936C>T germinal polymorphism on tumoral VEGF expression in head and neck cancer. Pharmacogenomics (2009) 0.92
Results of vocal rehabilitation using tracheoesophageal voice prosthesis after total laryngectomy and their predictive factors. Eur Arch Otorhinolaryngol (2009) 0.92
A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit (2006) 0.91
Significance of circulating tumor cell detection using the CellSearch system in patients with locally advanced head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol (2013) 0.90
Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan. Br J Clin Pharmacol (2012) 0.90
Long-term quality of life and its predictive factors after oncologic surgery and microvascular reconstruction in patients with oral or oropharyngeal cancer. Eur Arch Otorhinolaryngol (2013) 0.89
Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer. Crit Rev Oncol Hematol (2008) 0.89
Oxaliplatin-5-fluorouracil and ionizing radiation. Importance of the sequence and influence of p53 status. Oncology (2003) 0.88
Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chemotherapy. Gastroenterology (2014) 0.88
Dual role of Sp3 transcription factor as an inducer of apoptosis and a marker of tumour aggressiveness. PLoS One (2009) 0.88
Impact of glycosylation on the effect of cytokines. A special focus on oncology. Eur Cytokine Netw (2002) 0.88
Epidermal growth factor receptor protein detection in head and neck cancer patients: a many-faceted picture. Clin Cancer Res (2012) 0.86
Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience. PLoS One (2013) 0.86
Radical ablative surgery and radial forearm free flap (RFFF) reconstruction for patients with oral or oropharyngeal cancer: postoperative outcomes and oncologic and functional results. Acta Otolaryngol (2009) 0.85
Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure. J Clin Oncol (2010) 0.85
Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition. Eur J Cancer (2008) 0.85
Persistent twenty-four hour changes in liver and bone marrow despite suprachiasmatic nuclei ablation in mice. Am J Physiol Regul Integr Comp Physiol (2004) 0.85
A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule. Clin Pharmacokinet (2007) 0.84
The impact of pharmacogenetics on radiation therapy outcome in cancer patients. A focus on DNA damage response genes. Cancer Treat Rev (2012) 0.84
Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation. Mol Cancer Ther (2005) 0.84
Quality of life after oral and oropharyngeal reconstruction with a radial forearm free flap: prospective study. J Otolaryngol Head Neck Surg (2009) 0.83
Emerging molecular targeted therapies in the treatment of head and neck cancer. Expert Opin Emerg Drugs (2009) 0.83
Personalized medicine in oncology: where have we come from and where are we going? Pharmacogenomics (2013) 0.83
Long-term functional outcomes and quality of life after oncologic surgery and microvascular reconstruction in patients with oral or oropharyngeal cancer. Acta Otolaryngol (2014) 0.83
Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives. Anticancer Agents Med Chem (2013) 0.82
A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 0.82
The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data. BJU Int (2008) 0.82
Ablative surgery and free flap reconstruction for elderly patients with oral or oropharyngeal cancer: oncologic and functional outcomes. Acta Otolaryngol (2011) 0.81
Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004-02). Clin Cancer Res (2012) 0.81
Epidermal growth factor receptor/angiogenesis dual targeting: preclinical experience. Curr Opin Oncol (2006) 0.81
Synchronous parathyroid and papillary thyroid carcinomas. Thyroid (2009) 0.81
Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs. Expert Opin Drug Metab Toxicol (2014) 0.81
Nuclear localization of a novel human syntaxin 1B isoform. Gene (2008) 0.80
Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft. Eur J Cancer (2005) 0.80
PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer. Cancer Med (2015) 0.79
Oral cavity squamous cell carcinoma in 260 patients aged 80years or more. Radiother Oncol (2009) 0.79
A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients. Clin Cancer Res (2009) 0.79
Genetic and biochemical modulation of 5-fluorouracil through the overexpression of thymidine kinase: an in-vitro study. Anticancer Drugs (2006) 0.79
Antitumor activity of cetuximab associated with the taxotere-cisplatin-fluorouracil (TPF) combination on an orthotopic head and neck cancer model. Oral Oncol (2011) 0.78
Impact of erythropoietin on the effects of irradiation under hypoxia. J Cancer Res Clin Oncol (2009) 0.78
Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line. Urol Oncol (2011) 0.78
Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment. Nucleosides Nucleotides Nucleic Acids (2014) 0.78
Overexpression of cortactin in head and neck squamous cell carcinomas can be uncoupled from augmented EGF receptor expression. Acta Oncol (2008) 0.78
Tapered dose versus constant drug exposure to anti-EGFR drugs on head-and-neck cancer xenografts. A comparison between cetuximab and gefitinib. Oral Oncol (2010) 0.78